Hughes Biotech Showcases Scientific-Based Precision Gene Regulation and RenoSorb™ Technology Platform at BIO USA 2026
[San Diego, USA] — Representing Taiwan’s robust innovation energy at the BIO International Convention (BIO USA), Hughes Biotech is announcing a strategic leap: transitioning its novel active compounds from the premium nutraceutical market into the frontier of pharmaceutical drug development.
For pharma companies focused on botanical drug discovery, Hughes Biotech serves as a comprehensive strategic partner, providing vital technical, material, and clinical support resources.
At the core of this advancement is the proprietary RenoSorb™ technology platform. Engineered for multiple targets applications, RenoSorb™ enables scientific-based, precision regulation of gene targets. By overcoming traditional oral bioavailability barriers, the platform ensures plant-derived active compounds achieve the optimized efficacy and target-specific absorption required for drug-grade therapeutics.
What sets Hughes Biotech apart is its proven track record. Backed by successful clinical application cases, Hughes delivers fully validated, evidence-based solutions that offer pivotal clinical support for pharma pipelines rather than just phyto-ingredients.
By showcasing these clinical milestones and robust R&D capabilities at BIO USA, Hughes Biotech is ready to forge strategic alliances with global pharmaceutical leaders to drive the future of precision medicine.
